- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
John F. D. Dipersio, MD, PhD | Authors
Perspectives on COVID-19 Prophylaxis and Vaccination
May 19, 2022
To close the discussion, panelists reflect on their practices’ guidance on long-acting antibody prophylaxis and vaccination against COVID-19 for patients with graft-versus-host-disease (GVHD).
Treatment Approaches Using Ruxolitinib in GVHD
May 12, 2022
In a discussion on the use of ruxolitinib in GVHD, experts consider the potential role of dose reductions or dose holds to mitigate toxicity and comment on experiences with combining or sequencing therapies in later lines of treatment.
Additional Approaches for Steroid-Refractory Chronic GVHD
May 12, 2022
Expert panelists comment on additional treatment options for significant steroid-refractory chronic GVHD following initial therapeutic intervention, including rechallenging with prophylactic agents or initiating B-cell therapy.
The Role of Photopheresis for GVHD Following Progression
May 05, 2022
A panel of experts shares key insights into the role of photopheresis when patients with GVHD progress following initial treatment and emphasize its potential for patients with high skin involvement.
Clinical Scenario 2: Steroid-Refractory Chronic GVHD
May 05, 2022
Key opinion leaders in stem cell transplant and cellular immunotherapy review therapeutic considerations for the clinical scenario of a patient with steroid-refractory chronic GVHD.
The Effect of Trial Design on Approval of GVHD Therapies
April 28, 2022
Panelists consider the importance of studying trial drugs in a blinded, randomized fashion to mitigate physician and patient bias regarding patient-reported outcomes for GVHD therapies.
Clinical Scenario 1: First- and Second-Line Treatment for GVHD
April 28, 2022
John F. DiPersio, MD, PhD, presents the clinical scenario of a 71-year-old patient postmatched unrelated donor HSCT, and the panel discusses first- and second-line treatment approaches including topical and systemic therapies.
The Role of Prophylaxis Regimens for GVHD
April 21, 2022
Yi-Bin Chen, MD, reviews factors affecting treatment selection among available pharmacological and ex vivo prophylaxis approaches for GVHD.
Counseling Patients on the Long-Term Management of GVHD
April 21, 2022
Thought leaders in stem cell transplant and cellular immunotherapy share insights into how they counsel patients about the challenges associated with the long-term management of chronic GVHD.
Chronic GVHD Risk Factors and Prevention
April 14, 2022
Panelists consider key risk factors for chronic GVHD, including the degree of donor transplant matching, patient age, intensity of conditioning, use of ablative doses of total-body radiation, and presence of acute GVHD.